BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $RARE readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06636071-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~setrusumab readout (P3) · Ultragenyx Pharmaceutical Inc $RARE
DESCRIPTION:Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imp
 erfecta\n\nPrimary completion date: 2027-01 (estimated) — month only\, s
 hown on the 1st\nPhase 3 · Rare · Osteogenesis Imperfecta\nEnrollment: 6
  · Sites: 3\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT06636071\nhttps://clinicaltrials.gov/study/NCT0
 6636071
URL:https://datacutoff.com/radar.html?nct=NCT06636071
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04360265-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~No Investigational Product readout (P3) · Ultragenyx Pharmaceutic
 al Inc $RARE
DESCRIPTION:Follow-up Study of AAV-Mediated Gene Transfer (UX111\; Previous
 ly Known as ABO-102) for MPS Type IIIA\n\nPrimary completion date: 2027-08
  (estimated) — month only\, shown on the 1st\nOriginally planned: 2025-1
 2-31 (+19.0 months)\nPhase 3 · Rare · Mucopolysaccharidosis IIIA\, MPS I
 IIA\, Sanfilippo Syndrome\nEnrollment: 41 · Sites: 4\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT043602
 65\nhttps://clinicaltrials.gov/study/NCT04360265
URL:https://datacutoff.com/radar.html?nct=NCT04360265
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933200-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Triheptanoin readout (P3) · Ultragenyx Pharmaceutical Inc $RARE
DESCRIPTION:A Study to Determine the Effect of Triheptanoin Compared With E
 ven-Chain MCT on MCEs in Pediatric Patients With LC-FAOD\n\nPrimary comple
 tion date: 2027-08 (estimated) — month only\, shown on the 1st\nOriginal
 ly planned: 2026-09 (+11.0 months)\nPhase 3 · Other · Long-chain Fatty A
 cid Oxidation Disorders (LC-FAOD)\nEnrollment: 69 · Sites: 15\n\nPrimary 
 completion = last participant's primary-endpoint data collected\; topline 
 results usually follow weeks to months later. Sponsor-reported\, often an 
 estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT05933200\nhttps://clinicaltrials.gov/study/NCT05933200
URL:https://datacutoff.com/radar.html?nct=NCT05933200
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05345171-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~DTX301 readout (P3) · Ultragenyx Pharmaceutical Inc $RARE
DESCRIPTION:Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithi
 ne Transcarbamylase (OTC) Deficiency\n\nPrimary completion date: 2027-09 (
 estimated) — month only\, shown on the 1st\nOriginally planned: 2024-12 
 (+33.0 months)\nPhase 3 · Rare · OTC Deficiency\nEnrollment: 37 · Sites
 : 16\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com
 /radar.html?nct=NCT05345171\nhttps://clinicaltrials.gov/study/NCT05345171
URL:https://datacutoff.com/radar.html?nct=NCT05345171
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
